NCT03706885View on ClinicalTrials.gov

Efavirenz for Patients With Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 5, 2018

Primary Completion Date

January 28, 2022

Study Completion Date

January 28, 2022

Conditions
Alzheimer Disease, Early Onset
Interventions
DRUG

Sustiva Pill

One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks

Trial Locations (1)

44122

University Hospitals Brain Health and Memory Center, Beachwood

All Listed Sponsors
collaborator

University Hospitals Cleveland Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Case Western Reserve University

OTHER

NCT03706885 - Efavirenz for Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter